Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
Citizens Financial Services
CZFS
$387M
| $68.9K | ﹤0.01% |
1,549
-1,123
| -42% | -$48.1K |
|
|
CTV
3927
DELISTED
Innovid Corp.
CTV
| $68.7K | ﹤0.01% |
37,153
-74,159
| -67% | -$159K |
|
3928
Plumas Bancorp
PLBC
$429M
| $68.6K | ﹤0.01% |
1,906
-1,910
| -50% | -$67.1K |
|
3929
Vitamin Cottage Natural Grocers
NGVC
$654M
| $68.3K | ﹤0.01% |
3,224
-3,300
| -51% | -$62.8K |
|
3930
Unilever
UL
$136B
| $68.3K | ﹤0.01% |
1,104
-409
| -27% | -$24.2K |
|
3931
Orchestra BioMed
OBIO
$254M
| $67.9K | ﹤0.01% |
8,337
-2,111
| -20% | -$12.2K |
|
|
BOLD
3932
Boundless Bio
BOLD
$65M
| $67.6K | ﹤0.01% |
17,476
+2,476
| +17% | +$23.7K |
|
3933
Avita Medical
RCEL
$240M
| $67.5K | ﹤0.01% |
8,524
-11,812
| -58% | -$112K |
|
3934
Sprott Uranium Miners ETF
URNM
$2B
| $67.4K | ﹤0.01% |
1,368
-11,476
| -89% | -$608K |
|
3935
VistaGen Therapeutics
VTGN
$12.8M
| $67K | ﹤0.01% |
19,261
-3,816
| -17% | -$16.5K |
|
3936
Aquestive Therapeutics
AQST
$494M
| $67K | ﹤0.01% |
+25,770
| New | +$86.1K |
|
|
PINE
3937
Alpine Income Property Trust
PINE
$352M
| $66.8K | ﹤0.01% |
4,292
-4,516
| -51% | -$69.1K |
|
3938
Vanguard FTSE Europe ETF
VGK
$31.1B
| $66.8K | ﹤0.01% |
1,000
-273,200
| -100% | -$18.5M |
|
|
TE
3939
T1 Energy
TE
$1.63B
| $66.7K | ﹤0.01% |
39,243
-140,757
| -78% | -$269K |
|
3940
Weyco Group
WEYS
$440M
| $66.7K | ﹤0.01% |
2,200
-2,018
| -48% | -$59.7K |
|
3941
Quantum-Si Incorporated
QSI
$177M
| $66.6K | ﹤0.01% |
63,388
-37,967
| -37% | -$60.9K |
|
|
XOMA
3942
DELISTED
Xoma
XOMA
| $66.5K | ﹤0.01% |
2,809
-2,352
| -46% | -$58.8K |
|
|
BLUE
3943
DELISTED
bluebird bio
BLUE
| $66.4K | ﹤0.01% |
3,373
-3,343
| -50% | -$67K |
|
3944
Lexicon Pharmaceuticals
LXRX
$1.1B
| $66.3K | ﹤0.01% |
39,437
-25,182
| -39% | -$45.2K |
|
3945
Incannex Healthcare
IXHL
$37.7M
| $66.2K | ﹤0.01% |
+750
| New | +$64.7K |
|
3946
Vanguard Morningstar Value ETF
VTV
$192B
| $66.1K | ﹤0.01% |
412
| – | – |
|
|
ITI
3947
DELISTED
Iteris, Inc.
ITI
| $66K | ﹤0.01% |
15,231
-15,292
| -50% | -$69.2K |
|
3948
Lantronix
LTRX
$266M
| $65.9K | ﹤0.01% |
18,551
-35,872
| -66% | -$129K |
|
3949
Omega Flex
OFLX
$312M
| $65.4K | ﹤0.01% |
1,275
-1,808
| -59% | -$115K |
|
3950
Norwood Financial Corp
NWFL
$368M
| $65.3K | ﹤0.01% |
2,572
-2,494
| -49% | -$61.7K |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.